Working… Menu
Trial record 56 of 865 for:    LENALIDOMIDE AND Angiogenesis

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02255162
Recruitment Status : Terminated (Slow Accrual)
First Posted : October 2, 2014
Last Update Posted : August 18, 2017
Celgene Corporation
Information provided by (Responsible Party):
Amir Fathi, Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016